ArticleFrontiers in pediatrics2025
Endoscopic ultrasound safety and efficacy in pediatric pancreatobiliary and gastrointestinal disorders: single-center retrospective trial.
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While endoscopic ultrasound (EUS) is well established as a standard diagnostic and therapeutic tool in adults, its use in children remains limited. This study assessed the indications, safety, and clinical impact of diagnostic and therapeutic EUS in children with pancreatobiliary and gastrointestinal disorders. Methods: We retrospectively analyzed pediatric patients with pancreatobiliary and gastrointestinal disorders who underwent EUS at our institution between January 2022 and June 2025. Results: Fifty-three EUS procedures were conducted in children with a median age of 9.6 ± 3.0 years. Indications for EUS included acute recurrent pancreatitis ( Conclusion: EUS is safe and effective diagnostic and therapeutic modality in pediatric patients with pancreatobiliary and gastrointestinal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.